CJC-1295 & ipamorelin dosage: the circulated numbers vs. what's actually proven

“How much CJC-1295 and ipamorelin should I take” ranks among the top things people type into a search bar about this pair, and almost every answer online presents a tidy microgram number as if it were settled. It is not. There is no approved human dose for either compound — both are sold as research-grade peptides, so anything labeled a “dosage” is off-label and clinically unvalidated. What does exist is a layer of pharmacology that explains why the circulated numbers landed where they did, and a separate layer of forum and clinic convention that turned that pharmacology into specific injection routines. This page keeps those two layers apart. We cover the trial evidence on whether the pair even works in our companion ipamorelin & CJC-1295 evidence review — here, the subject is strictly the dosing logic and its limits.

Why the two are stacked in the first place

The dosing only makes sense once you see what each peptide contributes. They are paired precisely because they act on different switches of the same growth-hormone machinery, and combining them is meant to make a bigger, cleaner pulse than either produces alone. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone; a single injection in healthy adults kept GH and IGF-1 elevated for days rather than minutes — effectively raising the baseline from which the pituitary operates.^[1] Think of it as setting a sustained “floor.” Ipamorelin works through a separate door entirely: it is a selective agonist at the ghrelin (GH-secretagogue) receptor, and it was characterized as the first such compound that triggers a sharp GH release without dragging cortisol and prolactin up with it.^[2] Layered onto the CJC-1295 floor, that pulse rides higher. The whole dosing rationale — the timing, the splitting, the empty-stomach rule — follows from trying to land ipamorelin’s spike on top of CJC-1295’s plateau.

The “saturation dose” idea behind the ipamorelin numbers

The most repeated ipamorelin figures — usually quoted in the low hundreds of micrograms per injection — trace back to a single pharmacology concept rather than a dose-finding study in people. The reasoning runs like this: a GH secretagogue produces a pulse that grows with dose up to a point, after which the receptor response flattens and extra peptide buys little extra GH. The amount near that flattening point gets called a “saturation dose,” and the weight-based version of it — roughly a single microgram for every kilogram a person weighs — is where the commonly circulated per-injection numbers come from. That is a reasonable way to reason about a ceiling, but it is worth being blunt about what it is not: it is not the output of a randomized dosing trial in healthy adults, and a dose that maximizes a hormone spike is not the same as a dose shown to change body composition. The published clinical record on whether secretagogues meaningfully move downstream markers is thin; one study in hypogonadal men found that secretagogue treatment did raise serum IGF-1, confirming the axis responds — but raising a marker is the start of the question, not the end of it.^[3]

What anchors the CJC-1295 number

CJC-1295 is the cleaner half of the dosing story, because at least one human figure rests on actual measurement. The pharmacokinetic study that established its prolonged action gave healthy adults a single, fixed injection and then tracked GH and IGF-1 over the following days.^[1] That defined amount is the closest thing the pair has to a “studied dose” — but notice what it was studied for: the trial measured hormone kinetics, not whether the injection built muscle, burned fat, or improved any outcome a buyer actually cares about. So the CJC-1295 number is better grounded than the ipamorelin one, yet it inherits the same fundamental gap. A dose can be precisely characterized for what it does to a lab value and still be entirely unproven for the result it is marketed to deliver.

What gets circulated: the reported protocols, with caveats

With both caveats firmly in place, here is the shape of what is actually passed around in clinic and bodybuilding contexts — described, not endorsed. The pair is typically reconstituted from lyophilized powder and injected subcutaneously. Timing is the part everyone obsesses over: the pulse is usually placed on an empty stomach, most often at night before sleep, because a recent meal’s rise in blood sugar and insulin is thought to blunt the GH response. The reported cadences range from a single nightly injection to two or three spread across the day in heavier “bodybuilding” routines, and many of the circulated regimens are run in cycles — weeks on, then a break — rather than indefinitely. None of those choices — the nightly timing, the multi-daily splitting, the cycling — comes from a controlled human trial; they are conventions that hardened through repetition. The table below lays out how the two peptides differ on the variables that drive any dosing decision, so the logic is visible rather than buried in a number.

Bodybuilding dosing is more, not better-evidenced

The heavier regimens promoted in physique and “bodybuilding dosage” contexts — larger per-shot amounts, more injections per day, longer uninterrupted runs — do not sit on a stronger evidence base than the conservative ones. They sit on the same absent foundation, scaled up. Pushing past the saturation idea is unlikely to keep extracting more GH for free, and it does plausibly increase the downside: chronic, aggressive stimulation of the GH/IGF-1 axis is exactly the pattern that raises the unresolved questions about glucose handling, fluid retention, and tissue growth. “More” here buys more uncertainty, not more proof.

Who should not be reaching for these at all

Independent of any number, several groups have clear reasons to steer well clear without specialist oversight: anyone with a current or past cancer or active concern about it (because of the IGF-1 and tissue-growth questions), people with diabetes or impaired glucose tolerance (the axis can worsen glucose handling), pregnant or breastfeeding people, anyone under eighteen, and anyone already taking medications or managing conditions that intersect with hormones or metabolism. For these groups the honest answer to “what dose” is not a smaller dose — it is a clinician conversation before anything else.

The honest bottom line

The circulated CJC-1295 and ipamorelin doses are real in the sense that lots of people use them — and unreal in the sense that none of them carry the thing a dose is supposed to carry: a regulator’s approval and a trial showing the number produces the promised result. The pharmacology is legitimate and even elegant: a long-acting GHRH floor, a clean secretagogue pulse, a saturation ceiling. But pharmacology explains where the numbers came from; it does not validate them as therapy. If you are weighing this stack, the appropriate next moves are a licensed clinician, a clear-eyed look at the evidence, the real cost of the blend, and a plan for sourcing safely — not a microgram figure copied from a thread. For context on related compounds, our sermorelin dosage page and ipamorelin vs. sermorelin comparison are useful, and you can size up the broader category in our peptide therapy cost breakdown, our vetted peptide-therapy providers, and the peptide evidence matrix.